Features | Partner Sites | Information | LinkXpress
Sign In
SCHILLER AG
TERARECON, INC.
AMPRONIX

Risk of Breast Cancer Later in Life for Girls Undergoing Radiotherapy Explained

By Medimaging International staff writers
Posted on 02 Oct 2013
Image: Computation model of the developing mammary gland beginning at three weeks of age (Photo courtesy of the US Department of Energy’s Lawrence Berkeley National Lab’s Life Sciences Division
Image: Computation model of the developing mammary gland beginning at three weeks of age (Photo courtesy of the US Department of Energy’s Lawrence Berkeley National Lab’s Life Sciences Division
Exposing young women and girls under the age of 20 to ionizing radiation can substantially raise the risk of their developing breast cancer later in life. Scientists may now have found the answer as to why this occurs. A collaborative study’s findings pointed to increased stem cell self-renewal and consequential mammary stem cell enrichment as the reason.

Breasts enriched with mammary stem cells as a result of ionizing irradiation during puberty show a later-in-life propensity for developing estrogen receptor (ER)-negative tumors. Estrogen receptors, i.e., proteins activated by the estrogen hormone, are vital for the normal development of the breast and other female sexual features during puberty.

“Our results are in agreement with epidemiology studies showing that radiation-induced human breast cancers are more likely to be ER-negative than are spontaneous breast cancers,” said Dr. Sylvain Costes, a biophysicist with US Department of Energy’s (DOE) Lawrence Berkeley National Lab’s Life Sciences Division (LBL; Berkeley, CA, USA). “This is important because ER-negative breast cancers are less differentiated, more aggressive, and often have a poor prognosis compared to the other breast cancer subtypes.”

Drs. Costes and Jonathan Tang, also with Berkeley Lab’s Life Sciences Division, were part of a collaboration led by Dr. Mary Helen Barcellos-Hoff, formerly with Berkeley Lab and now at the New York University School of Medicine (New York, NY, USA), that studied the so-called “window of susceptibility” known to exist between radiation treatments at puberty and breast cancer risk in later adulthood. The key to their success were two mammary lineage agent-based models (ABMs) they developed in which a system is modeled as a collection of autonomous decision-making units called agents. One ABM simulated the effects of radiation on the mammary gland during either the developmental stages or during adulthood. The other simulated the growth dynamics of human mammary epithelial cells in culture after irradiation.

“Our mammary gland ABM consisted of millions of agents, with each agent representing either a mammary stem cell, a progenitor cell or a differentiated cell in the breast,” stated Dr. Tang. “We ran thousands of simulations on Berkeley Lab’s Lawrencium supercomputer during which each agent continually assessed its situation and made decisions on the basis of a set of rules that correspond to known or hypothesized biological properties of mammary cells. The advantage of this approach is that it allows us to view the global consequences to the system that emerge over time from our assumptions about the individual agents. To our knowledge, our mammary gland model is the first multiscale model of the development of full glands starting from the onset of puberty all the way to adulthood.”

Epidemiologic research have shown that girls under 20 administered radiotherapy treatment for disorders such as Hodgkin’s lymphoma have about the same risk of developing breast cancer in their 40s as women who were born with a BRCA gene mutation. From their study, Drs. Costes, Tang, and their colleagues concluded that self-renewal of stem cells was the most likely responsible process.

“Stem cell self-renewal was the only mechanism in the mammary gland model that led to predictions that were consistent with data from both our in vivo mouse work and our in vitro experiments with MCF10A, a human mammary epithelial cell line,” Dr. Tang noted. “Additionally, our model predicts that this mechanism would only generate more stem cells during puberty while the gland is developing and considerable cell proliferation is taking place.”

The investigators are now looking for genetic or phenotypic biomarkers that would identify young girls who are at the greatest breast cancer risk from radiotherapy. The study’s findings from Dr. Barcellos-Hoff and her research group show that the ties between ionizing radiation and breast cancer extend beyond DNA damage and mutations.

“Essentially, exposure of the breast to ionizing radiation generates an overall biochemical signal that tells the system something bad happened,” Dr. Costes said. “If exposure takes place during puberty, this signal triggers a regenerative response leading to a larger pool of stem cells, thereby increasing the chance of developing aggressive ER-negative breast cancers later in life.”

The findings of this collaborative study have been published online August 23, 2013, in the journal Stem Cells.

Related Links:

Lawrence Berkeley US National Lab’s Life Sciences Division



RADCAL
RTI ELECTRONICS AB
SuperSonic Imagine

Channels

MRI

view channel
Image: The quantitative character of the novel 3D technique on MR scans from a patient with primary liver cancer is demonstrated. Images A and B show the scan of the patient before being treated with chemoembolization. The new 3D technique helped quantify the volume and distribution of viable tumor tissue (shown in red and yellow colors). Images C and D demonstrate MR scans acquired after the treatment. The new 3D method helped the radiologists to quantify the vast central destruction of the tumor after the treatment (the dead tumor is represented by the blue color) (Photo courtesy of Johns Hopkins Medicine).

3D MRI Offers Improved Prediction of Survival After Chemotherapy for Liver Tumors

Researchers are using specialized three-dimensional (3D) magnetic resonance imaging (MRI) scanning technology to accurately measure living and dying liver tumor tissue in order to quickly show whether... Read more

Ultrasound

view channel
Image: Siemens Healthcare has launched the HELX Evolution, the newest iteration of its Acuson S range of ultrasound imaging systems (Photo courtesy of Siemens Healthcare).

Ultrasound Imaging System Enhancements Include High Definition Transducers, Sophisticated Elastography, and Tissue Strain Analysis

New features designed for a range of ultrasound systems include enhanced image quality with a large 21.5-inch liquid crystal diode (LCD) monitor, high definition (HD) transducers, optimized contrast agent... Read more

Nuclear medicine

view channel
Image: Sagittal section of brain PET image at four hours after 64CuCl2 injection with disulfiram or D-penicillamine in MD model mice (Photo courtesy of the RIKEN Center for Life Science Technologies).

PET Imaging Used to Assess Effectiveness of Menkes Disease Treatments

Japanese scientists are using positron emission tomography (PET) imaging to visualize the distribution of copper in the body using lab mice. Copper distribution is deregulated in a genetic disorder called... Read more

General/Advanced Imaging

view channel

Secondary Light Emission Generated by Plasmonic Nanostructures May Improve Medical Imaging Technology

New clues into light emission at different wavelengths generated by elements known plasmonic nanostructures may help to improve medical imaging technology. A plasmon is a quantum of plasma oscillation. The plasmon is a quasiparticle resulting from the quantization of plasma oscillations just as photons, and phonons are... Read more

Imaging IT

view channel

Software Designed for the Assessment of Orthopedic Implant Fixation and Bone Segment Motion

Model-based roentgen stereophotogrammetric analysis (MBRSA) software has been developed for evaluation of orthopedic implant fixation and bone segment motion. The software is the first to measure the in vivo three-dimensional (3D) position and/or relative motion of metal implants, markers beads, and/or bone segments in... Read more

Industry News

view channel

Collaboration Expands Capacity for Proton Therapy Clinical Research and Patient Treatments

Varian Medical Systems (Palo Alto, CA, USA) and the Paul Scherrer Institute (PSI; Villigen PSI, Switzerland) are extending an existing collaboration in the field of proton therapy to offer patients more accurate cancer treatments using intensity-modulated proton therapy (IMPT). Under the agreement, Varian will also... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.